Business
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress.
About this update from Antengene Corporation Limited
[{"type":"text","content":"SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress.","length":279,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Antengene Corporation Limited)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Antengene Corporation Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":170,"url":"https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uUtsBM2BMi0O_Tqb3y2bow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwMA--/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583","width":400,"height":170}},"href":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, commented, "Over 2025 and prior years, Antengene has built a solid foundation for long-term growth, including a robust late-stage clinical pipeline, the proprietary AnTenGager™ T-cell engager (TCE) platform, and the commercialization of XPOVIO®, which is generating revenue across 10 APAC markets. As we enter into 2026, we are beginning to translate this foundation into tangible value creation. Our recent global licensing agreement with UCB for ATG-201 (CD19×CD3 TCE) represents the first out-licensing transaction for the company and the AnTenGager™ platform, validating its global competitiveness and marks a clear inflection point for Antengene. Antengene will receive USD 80 million (comprised of an initial upfront payment of USD 60 million and additional near-term milestone payments of USD 20 million), and is eligible to receive more than USD 1.1 billion in success-based development, regulatory and sales milestones, along with tiered royalties on future net sales.","length":1039,"tagName":"p"},{"type":"text","content":"At the same time, our late-stage clinical programs continue to advance. ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) has demonstrated strong efficacy and best-in-class safety in gastric cancer and other CLDN18.2+ solid tumors, with frontline combination studies in g...